Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Qui est le CEO de Newron Pharmaceuticals SpA ?
Prof. Stefan Weber est le Chief Executive Officer de Newron Pharmaceuticals SpA, il a rejoint l'entreprise depuis 2005.
Quelle est la performance du prix de l'action NWPHF ?
Le prix actuel de NWPHF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Newron Pharmaceuticals SpA ?
Newron Pharmaceuticals SpA appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Newron Pharmaceuticals SpA ?
La capitalisation boursière actuelle de Newron Pharmaceuticals SpA est de $0
Est-ce que Newron Pharmaceuticals SpA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Newron Pharmaceuticals SpA, y compris 3 achat fort, 4 achat, 1 maintien, 0 vente et 3 vente forte
